4,174 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Copley Financial Group Inc.

Copley Financial Group Inc. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,174 shares of the company's stock, valued at approximately $676,000. Johnson & Johnson makes up 0.6% of Copley Financial Group Inc.'s investment portfolio, making the stock its 27th biggest position.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vinva Investment Management Ltd boosted its stake in Johnson & Johnson by 6.8% during the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock worth $17,988,000 after buying an additional 7,110 shares during the last quarter. Financial Counselors Inc. grew its holdings in shares of Johnson & Johnson by 5.3% in the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock valued at $29,996,000 after purchasing an additional 9,309 shares during the period. Meridian Financial Partners LLC purchased a new position in Johnson & Johnson during the second quarter worth about $1,626,000. Meridian Investment Counsel Inc. grew its stake in shares of Johnson & Johnson by 19.6% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock valued at $3,667,000 after buying an additional 3,710 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock valued at $2,858,543,000 after buying an additional 102,502 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on JNJ shares. Morgan Stanley increased their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research report on Wednesday, November 6th. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 14th. Finally, Wells Fargo & Company upped their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.73.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $0.36 during midday trading on Friday, hitting $146.60. 8,323,370 shares of the stock were exchanged, compared to its average volume of 7,123,697. The stock has a market cap of $352.96 billion, a P/E ratio of 21.16, a PEG ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a 50 day moving average price of $157.01 and a 200-day moving average price of $156.28. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the firm earned $2.66 earnings per share. The company's revenue for the quarter was up 5.2% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.